Details of the Drug
General Information of Drug (ID: DMBJXCF)
Drug Name |
2pyrrolidin-1-yl-1-phenylpentan-1-one
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
14530-33-7; alpha-PVP; 1-Phenyl-2-(pyrrolidin-1-yl)pentan-1-one; alpha-pyrrolidinovalerophenone; Desmethyl pyrovalerone; Alpha-Pyrrolidinopentiophenone; CHEMBL205082; 1-Pentanone, 1-phenyl-2-(1-pyrrolidinyl)-; Flakka; beta-Ketone-prolintane; Prolintanone; Gravel; beta-Keto-prolintane; a-PVP; 2pyrrolidin-1-yl-1-phenylpentan-1-one; 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone; a-Pyrrolidinopentiophenone; O-2387; SCHEMBL4936204; DTXSID70456954; YDIIDRWHPFMLGR-UHFFFAOYSA-N; MFCD24386810; BDBM50182584; alpha-Pyrrolidinopentiophenone, a-PVP
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||
Structure | ||||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 231.33 | ||||||||||||||||||
Topological Polar Surface Area (xlogp) | 3.4 | |||||||||||||||||||
Rotatable Bond Count (rotbonds) | 5 | |||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | |||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | |||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References